Payment overview · 2025
General Payments
$845.14
36 reported records · 12 companies
Healthcare provider profile · identity verified
Jorge Martinez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DONNA, TX · NPI 1508864729
Verified facts
What the public records show
CMS Open Payments records show Jorge Martinez, M.D. received $845.14 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $217.19 | 25.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $159.65 | 18.9% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $93.29 | 11.0% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $81.18 | 9.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.16 | 8.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.97 | 7.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.77 | 4.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.32 | 3.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.29 | 3.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.45 | 2.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.38 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.49 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $845.14 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $203.52 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $116.63 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $109.57 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $109.57 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $93.29 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $81.18 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.16 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $65.97 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $50.08 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.32 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 262 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 227 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 221 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
262 | 64 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
227 | 55 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
227 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
103 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
221 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 857 | 291 |
| Losartan Potassium | Losartan Potassium | 464 | 147 |
| Metformin Hcl | Metformin Hcl | 422 | 139 |
| Lisinopril | Lisinopril | 350 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 108 |
| Gabapentin | Gabapentin | 309 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 108 |
| Furosemide | Furosemide | 264 | 76 |
| Farxiga | Dapagliflozin Propanediol | 262 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 83 |
| Jardiance | Empagliflozin | 227 | 55 |
| Ozempic | Semaglutide | 221 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 24 |
| Omeprazole | Omeprazole | 178 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 56 |
| Famotidine | Famotidine | 176 | 47 |
| Tramadol Hcl | Tramadol Hcl | 151 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 125 | 44 |
| Alprazolam | Alprazolam | 115 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 36 |
| Naproxen | Naproxen | 113 | 41 |
| Baclofen | Baclofen | 107 | 38 |
| Trulicity | Dulaglutide | 103 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 36 |
| Trazodone Hcl | Trazodone Hcl | 101 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 43 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 87 | 26 |
| Carvedilol | Carvedilol | 85 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 24 |
| Clonazepam | Clonazepam | 83 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 23 |
| Lorazepam | Lorazepam | 80 | 16 |
| Prednisone | Prednisone | 77 | 54 |
| Linzess | Linaclotide | 76 | 16 |
| Mounjaro | Tirzepatide | 75 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 26 |
| Meloxicam | Meloxicam | 72 | 17 |
| Pregabalin | Pregabalin | 72 | 19 |
| Alendronate Sodium | Alendronate Sodium | 71 | 29 |
| Nifedipine Er | Nifedipine | 71 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 67 | 54 |
| Finasteride | Finasteride | 64 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 64 | 26 |
| Meclizine Hcl | Meclizine Hcl | 63 | 24 |
| Montelukast Sodium | Montelukast Sodium | 62 | 22 |
| Telmisartan | Telmisartan | 61 | 18 |
| Tradjenta | Linagliptin | 58 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 58 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 18 |
| Clonidine Hcl | Clonidine Hcl | 55 | 28 |
| Eliquis | Apixaban | 55 | 17 |
| Donepezil Hcl | Donepezil Hcl | 52 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 51 | 24 |
| Valsartan | Valsartan | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | 17 |
| Buspirone Hcl | Buspirone Hcl | 45 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 17 |
| Sertraline Hcl | Sertraline Hcl | 44 | 20 |
| Ibuprofen | Ibuprofen | 43 | 19 |
| Irbesartan | Irbesartan | 43 | 13 |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 25 |
| Glipizide | Glipizide | 39 | 16 |
| Ezetimibe | Ezetimibe | 36 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Enalapril Maleate | Enalapril Maleate | 34 | 11 |
| Mupirocin | Mupirocin | 34 | 24 |
| Xarelto | Rivaroxaban | 34 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 30 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 30 | 12 |
| Humalog Kwikpen U-200 | Insulin Lispro | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | 12 |
| Spironolactone | Spironolactone | 30 | 11 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Dexamethasone | Dexamethasone | 26 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 14 |
| Clotrimazole | Clotrimazole | 24 | 11 |
| Lactulose | Lactulose | 24 | 12 |
| Novolog Flexpen | Insulin Aspart | 24 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Scopolamine | Scopolamine | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 13 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 18 | 16 |
| Allopurinol | Allopurinol | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Constulose | Lactulose | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Terconazole | Terconazole | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $845.14 · 36 records | AstraZeneca Pharmaceuticals LP | AREXVY, BREZTRI, CAPVAXIVE, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error